KEI panel on government funding of COVID drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest

On October 5, 2020, KEI organized a panel about government funding of COVID-19 drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest. Although the full Global Congress event was postponed to the year 2021, the… Continue Reading

Legislative Committee in Ecuador approves resolution on compulsory licensing of patents relating to the coronavirus

For more on KEI’s work on COVID-19, see keonline.org/coronavirus. Today, the Education, Culture, Science and Technology Commission of the National Assembly in Ecuador approved a resolution asking the Minister of Health to issue compulsory licenses over patents related to coronavirus… Continue Reading

Chilean Chamber of Deputies approves resolution for compulsory licenses for patents relating to the coronavirus virus

For more on KEI’s work on COVID-19, see keonline.org/coronavirus. Today, with an overwhelming 127 votes in favor and 0 votes against, the Chilean Chamber of Deputies approved a strong resolution asking the Chilean Government to declare that there is justification… Continue Reading

Three areas in Section 202 of the Bayh-Dole Act that require action to ensure sufficient rights in patents on coronavirus relevant inventions

For more on KEI’s work on COVID-19, see keonline.org/coronavirus. As the US and other governments begin to expend large amounts of money on research and development related to the control, prevention and treatment of the coronavirus pandemic, there are important… Continue Reading

U.K. Labour Leader Jeremy Corbyn calls for use of compulsory licensing, public sector manufacturing and pricing controls on drugs using government funded inventions

Today, in his address to the U.K. Labour party conference, Labour Leader Jeremy Corbyn made the following statement on drug patents and prices. Yesterday I met Luis Walker, a wonderful nine-year-old boy. Luis is living with cystic fibrosis. Every day… Continue Reading

KEI Memo on U.S. Legislation to cap price increases on prescription drugs and to enhance the transparency of R&D costs

On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs.  Congress is currently considering several bills that touch on these… Continue Reading

Italy’s Draft WHO resolution: Improving the transparency of markets for drugs, vaccines and other health-related technologies

On 1 February 2019, Dr. Giulia Grillo, Italy’s Minister of Health, sent a letter to Dr. Tedros Adhanom Ghebreyesus, the Director General of the World Health Organization (WHO), with an attached “first draft” of a resolution on “Improving the transparency… Continue Reading